비알팜

비상장계속사업자

BR PHARM CO.,Ltd.

김석순

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

비알팜

Business Reg. No. 1228187742 · CEO 김석순

I.Investment Overview

Target비알팜 (1228187742)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명비알팜
영문명BR PHARM CO.,Ltd.
대표자김석순
사업자등록번호1228187742
법인등록번호1201110380147
설립일2005.07.25

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW104.72021194.620222442023320.12024430.82025
영업이익100M KRW16.2202167.3202294.72023130.42024186.82025
순이익100M KRW13202159.3202280.82023113.82024136.32025
Item20252024202320222021
자산총계696.9억원506.5억원395억원288억원222.3억원
부채총계200.8억원146.7억원148.9억원122.7억원114.6억원
자본총계496.1억원359.8억원246억원165.2억원107.7억원
매출액430.8억원320.1억원244억원194.6억원104.7억원
영업이익186.8억원130.4억원94.7억원67.3억원16.2억원
순이익136.3억원113.8억원80.8억원59.3억원13억원

VI.Financial Ratios

FY2025 basis

43.36%

영업이익률

31.65%

순이익률

19.56%

ROA

27.48%

ROE

40.48%

부채비율

71.19%

자기자본비율

VII.R&D Activity

Fields 생명과학 > 산업바이오 · 보건의료 > 신약·의약품개발

Keywords 항노화, 폴리데옥시리보뉴클레오타이드, 주름개선, 화장품, 리포좀

YearProjectsPapersPatents
2021101
2020100
2019101
2018100
2017200

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

비알팜 투심보고서 | Alpha Lenz